Member Info for BuckFuzby

Yes. Phase 3 is well underway and they are looking to replicate the results from phase 2. The trial, so far, hasn't hit any complications and the DMC seem happy. Even though it's a double blind, management will have some markers that indicate it's potential success, such as the uptake and level of drop outs. Management see value in this long term, hence why they've decided to run it and not sell out cheaply and the NHS wants 001.

As for dilution, Professor Nutt seemed optimistic about accessing grants and the Investors who pumped capital in won't be wanting to dilute themselves to oblivion, so we will see.

This is only an opinion and risks still remain.

It probably means they are busy.

What are your thoughts and the potential impact this has on the company going forwards?

Https://www.watertowerresearch.com/media-detail/3684/Media

In this special episode of the WTR Healthcare Happenings podcast, the second in a two-part series, Professor David Nutt, Chief Science Officer of Solvonis Therapeutics (LSE: SVNS), talks to host Tim Gerdeman and WTR analyst Robert Sassoon about addiction and why he believes Solvonis' novel approach offers potentially better solutions than are currently available. The discussion also covers persistently low AUD treatment penetration, the favorable UK regulatory and reimbursement outlook versus US payer dynamics, how ketamine compares with emerging GLP-1 and psilocybin approaches, and the advantages of Solvonis' AI-enabled drug discovery platform. Finally, Nutt shares his thoughts on where the US federal addiction-research community actually is on psychedelic-assisted treatment for AUD and stimulant use disorder, following his recent presentation at the NIH ( National Institutes of Health) CRAN (Collaborative Research on Addiction) joint council as the sole external speaker on psychedelic therapy for addictions.

Professor Nutt seems very positive about accessing US grants.

Anthony is presenting tomorrow at 10am.

Conversation with Gemini

Can you type out the text in this picture, so I can copy and paste it into a word document

Here is the full text from the image, formatted and ready for you to copy and paste:

Solvonis Therapeutics

6,630 followers

19h • 🌐

Solvonis Therapeutics will be attending UK Biotech Day in London this week.

The event provides an opportunity to meet with companies, investors and sector colleagues across biotech, pharma, clinical development and life sciences investment.

For Solvonis Therapeutics, the focus is on building strategic conversations around #addiction and #psychiatry — areas of #CNS medicine where patient need remains high and therapeutic innovation has lagged.

The Company's pipeline is centred on high-burden #CNS disorders, including:

SVN-001 — UK Phase 3 programme in severe #AUD

SVN-002 — US-focused programme in moderate-to-severe #AUD

SVN-114 — #PTSD discovery programme

SVN-015 — stimulant use disorder programme selected for evaluation within NIDA’s Addiction Treatment Discovery Program

Partnering is an important part of biotech development. The right development, regulatory, clinical and commercial relationships can help shape how promising science progresses toward patients.

We look forward to engaging with the UK and international biotech community this week.

To arrange a meeting with Solvonis at UK Biotech Day, please contact us at info@solvonis.com.

$SVNS #UKBiotechDay #Biotech #CNS #AddictionMedicine #AlcoholUseDisorder #MentalHealth #Partnering

In this special episode of Healthcare Happenings, the first in a two-part series, Anthony Tennyson, CEO of Solvonis Therapeutics (LSE: SVNS), joins host Tim Gerdeman and WTR analyst Robert Sassoon to discuss the company’s strategy in addiction and psychiatry — a field with significant unmet need and limited effective treatment options. Anthony walks through SVN-001, a ketamine-based therapy for severe alcohol use disorder now in Phase 3 in the UK, and SVN-002, a U.S.-focused program targeting the much larger moderate-to-severe alcohol use disorder market. He also explains why Solvonis may not yet be fully recognized compared to its U.S.-listed peers.

Stay tuned for Part 2 next week with Professor David Nutt, Chief Scientific Officer of Solvonis, who unpacks the neuroscience behind SVN-001, the search for a better MDMA, and where psychedelic-assisted addiction therapy is headed.

https://www.watertowerresearch.com/media-detail/3653/Media

Hi Llama, it's saying it's expired.

Does anyone have a link to the group please?

Frustratingly, it has a couple of spelling errors in it.

I'm hoping so, but who knows.

Https://audioboom.com/posts/8895034-sunday-roast-featuring-rift-helium-solvonis-therapeutics-plc-and-karelian-diamond-resources-ri?playlist_direction=forward

It's all brewing away in the back ground , Hammer.

Patience, and the best pint of your life will be in your hands!

Hoping for news on 002, 015 and maybe 001 this week!

It's been frustrating, 5 months of waiting on news the licensing of 001, but I'm still hopeful.

Really hoping for a positive week.

Conversation with Gemini

SVNS trading pattern today

Today’s trading for Solvonis Therapeutics (SVNS) is characterized by high-volume "deck clearing" and a major ownership transfer during the early SETSqx auctions.

Following a period of compression, the pattern today suggests we are witnessing the final stages of a strategic supply overhang (a "wall" of shares from a large seller) being absorbed by the market.

1. Level 2 & The "Wall" Dynamics

The Level 2 order book today shows a heavy concentration of volume at the 0.26p - 0.27p support floor.

Spotting the Wall: Throughout the morning, large blocks (including a 3.15 million share print at 08:01:01) have hit the tape. This is a classic sign of a "Principal Trade" or a managed "Leak-Out" where a dominant institutional seller is fulfilling a quota.

Signs of a Break: We are seeing "Volume Exhaustion." While the price has drifted slightly, the trade frequency is decreasing despite high unit volume. This indicates the seller is running out of "ammo," and the liquidity vacuum behind the wall is starting to form.

2. SETSqx Auction Advantage

The 08:00 opening auction was the most significant event today, uncrossing the 3.1M block at 0.2699p.

The Strategy: Traders using the Auction Advantage look for these uncrossings to gauge the "true" demand. The fact that such a large block was absorbed without the price collapsing below 0.26p suggests that buyers (likely institutional) are waiting at this floor.

Next Milestone: The 11:00 intraday auction will be critical. If the uncrossing price holds above 0.27p, it confirms the "Transfer of Ownership" is complete and the overhead supply is exhausted.

Hello @ComesMarcellino thank you for your input. Just out of interest, which AI are you using to answer your questions?

@LlamaFarmer just out of interest, what signals that it's a single buyer?

Hey Bones, sorry the way this thread runs, my comment was for the original 'there's a leak, DYOR' poster.